C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke
Phase of Trial: Phase IV
Latest Information Update: 16 May 2018
At a glance
- Drugs Brain extract (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms C-REGS2
- Sponsors EVER Neuro Pharma
- 07 May 2018 Planned End Date changed from 31 Mar 2020 to 30 Sep 2020.
- 07 May 2018 Status changed from not yet recruiting to recruiting.
- 04 Apr 2018 Planned initiation date changed from 1 Apr 2018 to 15 Apr 2018.